OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Choi on Future Research Directions in CLL

January 17th 2022

Michael Choi, MD, discusses future research directions in chronic lymphocytic leukemia.

Dr. Gerds on the Rationale for the Real-World REVEAL Study in Polycythemia Vera

January 17th 2022

Aaron T. Gerds, MD, MS, discusses the rationale for the real-world REVEAL study in polycythemia vera.

Dr. Finn on the Utility of Belantamab Mafodotin in Late Relapsed Multiple Myeloma

January 17th 2022

Laura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.

Dr. Phillips Discusses Ongoing Trials in MCL

January 17th 2022

Tycel Jovelle Phillips, MD, discusses ongoing trials in mantle cell lymphoma.

Dr. Weiss on the Design of the KRYSTAL-10 Trial in KRAS G12C-Mutated CRC

January 17th 2022

Jared Weiss, MD, discusses the design of the phase 3 KRYSTAL-10 trial in KRAS G12C-mutated unresectable or metastatic colorectal cancer.

Dr. Meyer on Standard Treatment Options in Cardiac Angiosarcoma

January 14th 2022

Christian Frederick Meyer, MD, PhD, MS, discusses standard treatment options in cardiac angiosarcoma.

Dr. Azzi on the Rationale for the CIRCULATE Study in CRC

January 14th 2022

Georges Azzi, MD, discusses the rationale for the phase 3 CIRCULATE study in colorectal cancer.

Dr. Danilov on the Reduced Use of Chemoimmunotherapy in CLL

January 14th 2022

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Tolaney on the Efficacy of Zanidatamab Plus Chemo in HER2+ Breast Cancer

January 14th 2022

Sara M. Tolaney, MD, MPH, sheds light on zanidatamab and the data reported with the agent in combination with chemotherapy for the treatment of patients with HER2-positive breast cancer.

Dr. Gomella on the Challenges of Optimizing PSA as a Biomarker in Prostate Cancer

January 13th 2022

Leonard G. Gomella, MD, discusses the challenges of optimizing prostate-specific antigen as a biomarker in prostate cancer.

Dr. Ali on the Need to Understand Real-World Disparities in BRCA Testing in TNBC

January 13th 2022

Haythem Y. Ali, MD, member, Henry Ford Cancer Institute, Henry Ford Health System, discusses the need to understand real-world disparities with BRCA testing referrals and uptake in patients with triple-negative breast cancer.

Dr. Spaggiari on Surgical Strategies to Improve Liver Remnants in CRC With Liver Metastases

January 13th 2022

Mario Spaggiari, MD, discusses surgical strategies to improve liver remnants in colorectal cancer with liver metastases.

Dr. Mesa on JAK Inhibitors and Other Promising Novel Agents in Myelofibrosis

January 13th 2022

Ruben A. Mesa, MD, discusses JAK inhibitors and other promising agents in the myelofibrosis therapeutic landscape.

Dr. Burger on the Benefits of Novel Combination Approaches in CLL

January 13th 2022

Jan A. Burger, MD, PhD, discusses the benefit of combination therapy in patients with chronic lymphocytic leukemia.

Dr. Brander on the Role of MRD Negativity With Venetoclax-Based Regimens in CLL

January 13th 2022

Danielle M. Brander, MD, discusses the role of achieving minimal residual disease negativity with venetoclax-based regimens in chronic lymphocytic leukemia.

Dr. Toppmeyer on Sequencing Therapy in HER2+ Breast Cancer

January 12th 2022

Deborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.

Dr. Krop Discusses Progress Made in Metastatic HER2+ Breast Cancer

January 12th 2022

Ian E. Krop, MD, PhD, discusses progress made in 2021 in the management of HER2-positive breast cancer.

Dr. Brufsky on the Utility of Zanidatamab in HER2+ Breast Cancer

January 12th 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.

Dr. Hamid on the Differences in Evaluation Criteria for TIL Therapy in Melanoma

January 12th 2022

Omid Hamid, MD, discusses the differences in evaluation criteria for tumor-infiltrating lymphocytes therapy in melanoma.

Dr. Hamid on the Efficacy of TILs Following Immunotherapy in Advanced Melanoma

January 12th 2022

Omid Hamid, MD, discusses the efficacy of tumor-infiltrating lymphocyte therapy following immunotherapy in advanced melanoma.